As Vaccines Roll Out, Americans See COVID-19 Testing as Important Partner

- The development and authorization of a COVID-19 vaccine is a critical scientific milestone in our efforts to combat this pandemic. Abbott (NYSE: ABT) released findings today from a survey conducted by The Harris Poll, showing that Americans see testing as an essential partner to these new vaccines. Among the key findings:

  • Importance of Testing as Partner to Vaccine: 82% of Americans say the
    COVID-19 vaccine rollout will be more effective if it works in partnership with testing.
  • Precautionary Measures Support Vaccines: When asked whether a vaccine by itself or a layered strategy would help combat the pandemic and allow us to get back to normal as quickly as possible, 73% of Americans believe a COVID-19 vaccine cannot succeed without other precautionary measures . However, when asked about concerns following approval of a vaccine, many are concerned (very or somewhat) that testing (71%), mask wearing (75%), and social distancing (76%) will decline following vaccine authorization.

"Like the rest of the globe, Americans are anxious to return to normalcy. The authorization of vaccines is an important and tremendous development in our fight against COVID-19," said Andrea Wainer, executive vice president, Rapid and Molecular Diagnostics, Abbott. "Americans agree that we should stay vigilant in other important safety measures, including testing, mask wearing and social distancing. Abbott will remain focused on providing as many tests as possible so people can access them throughout the duration of the pandemic and beyond."

Since the onset of the pandemic, Abbott has launched eight COVID-19 tests for emergency use in the U.S. including lab-based and rapid molecular tests, antibody tests, and a rapid antigen test, which was recently authorized for at-home use with a prescription and certified virtual guide. Abbott has delivered more than 300 million COVID-19 tests worldwide.

As we await widespread access to the vaccine, Americans agree that testing remains essential to curbing the pandemic right now.

  • Role of Testing in Interim: 86% of Americans say testing will play a significant (very or somewhat) role in combatting the pandemic while we wait for vaccines to be made widely available.
  • Importance of Detecting Infectiousness: 66% of Americans say rapid antigen COVID-19 testing is a critical tool to combat the pandemic because of its ability to detect the most infectious people.

As initial doses of the vaccines are prioritized for populations like frontline healthcare workers and seniors in long-term care facilities, rapid antigen tests are as important as ever to identify infectious individuals and slow the spread of the virus among those who have not been vaccinated.

"With cases rising and critical winter months ahead, we must continue to use every preventative measure available to us to slow the spread of the virus," said Mary Rodgers , PhD., principal scientist, Diagnostics, Abbott. "It's important that diagnostic companies, public health leaders, policymakers and citizens continue to advocate for the role of vaccines and testing in partnership with other important safety measures like mask wearing, social distancing and hand washing."

This survey was conducted online within the United States by The Harris Poll on behalf of Abbott from December 10 December 14, 2020 , among 2,064 U.S. adults ages 18 and older.

For a summary of the data, please click here .

About Abbott
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 107,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com , on LinkedIn at www.linkedin.com/company/abbott-/ , on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews.

Cision View original content: https://www.prnewswire.com/news-releases/as-vaccines-roll-out-americans-see-covid-19-testing-as-important-partner-301197237.html

SOURCE Abbott

News Provided by PR Newswire via QuoteMedia

The Conversation (0)
Medtronic chairman and CEO Geoff Martha to speak at Bernstein's Strategic Decisions Conference

Medtronic chairman and CEO Geoff Martha to speak at Bernstein's Strategic Decisions Conference

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced it will participate in Bernstein's 41st Strategic Decisions Conference on Thursday, May 29, 2025 .

Geoff Martha , Medtronic chairman and chief executive officer, will make a formal presentation beginning at 11:00 a.m. EDT ( 10:00 a.m. CDT ). Immediately following the presentation, Martha will be joined by Thierry Piéton, Medtronic executive vice president and chief financial officer, to answer questions about the company.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Medtronic reports strong finish to its fiscal year with its fourth quarter financial results; announces dividend increase

Medtronic reports strong finish to its fiscal year with its fourth quarter financial results; announces dividend increase

Building momentum in key franchises including Pulsed Field Ablation, TAVR, Cardiac Rhythm Management, Diabetes, Spine, and Neuromodulation

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced financial results for its fourth quarter (Q4) and fiscal year 2025 (FY25), which ended April 25, 2025 .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Medtronic announces intent to separate Diabetes business

Medtronic announces intent to separate Diabetes business

Enables intense focus on highest margin growth drivers where Medtronic has leading core competencies

Leading, scaled, direct-to-consumer Diabetes business poised to become standalone company; only company with a complete ecosystem to address intensive insulin management

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones

Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones

  • FDA Breakthrough Device Designation Awarded to AVIM Therapy
  • FDA IDE Approved for Virtue SAB U.S. Pivotal Trial for Launch

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, "Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced financial results for the first quarter ended March 31, 2025, and provided a business update highlighting continued regulatory momentum, disciplined operational execution, and a strengthening clinical development pipeline.

Q1 2025 Highlights:

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Medtronic to announce financial results for its fourth quarter and full fiscal year 2025

Medtronic to announce financial results for its fourth quarter and full fiscal year 2025

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that it will report financial results for its fourth quarter and full fiscal year 2025 on Wednesday, May 21, 2025 . A news release will be issued at approximately 5:45 a.m. Central Daylight Time (CDT) and will be available at https:news.medtronic.com . The news release will include summary financial information for the company's fourth quarter and full fiscal year 2025, which ended on Friday, April 25, 2025 .

Medtronic will host a video webcast at 7:00 a.m. CDT on May 21, 2025 , to discuss results for its fourth quarter and full fiscal year 2025. The webcast can be accessed at https://investorrelations.medtronic.com .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
New survey: 1 in 3 women have not talked to their doctor about heart health, the #1 killer of women

New survey: 1 in 3 women have not talked to their doctor about heart health, the #1 killer of women

Star Jones , award winning television personality & women's heart health advocate,   helps kick off heart health conversations this Mother's Day with the Medtronic 'Letter to My Mother' campaign

A new Medtronic-sponsored survey of women ages 30-50 reveals a significant gap in awareness and discussion around heart health among women and their mother-figures. Despite cardiovascular disease being the #1 killer of women in the U.S. many women are still unaware of the risk and the importance of heart health.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×